


PHARMACEUTICAL 2019

Syros Pharmaceuticals Inc. Rank 137 of 363









PHARMACEUTICAL 2019



Syros Pharmaceuticals Inc. Rank 137 of 363

The relative strengths and weaknesses of Syros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Syros Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 102% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	101,734
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,529
Liabilities, Non-Current	0
Other Assets	1,171
Other Compr. Net Income	39
Other Expenses	0
Other Liabilities	0
Other Net Income	2,017
Other Revenues	2,050
Property and Equipment	3,861
Research and Development	50,182
Selling, General and Administrative Expense	16,164

Output Variable	Value in 1000 USD
Assets	106,766
Liabilities	19,529
Expenses	66,346
Revenues	2,050
Stockholders Equity	87,237
Net Income	-62,279
Comprehensive Net Income	-62,260
Economic Capital Ratio	139%

